Cannabigerol (CBG): Pharmacology, Evidence, and Safety Profile

This article is for informational purposes only and does not constitute medical or legal advice. Cannabis laws vary by jurisdiction. Consult a healthcare provider before using cannabinoid products, especially if taking medications.

By Kratom CBD Direct Editorial Team | Last verified: July 2026

What It Is: Chemical Identity and Natural Source

Cannabigerol (CBG) is a non-intoxicating cannabinoid and the decarboxylated form of cannabigerolic acid (CBGA)—the biosynthetic precursor from which all other major cannabinoids are synthesized. In the cannabis plant, CBGA is enzymatically converted into tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and other cannabinoid carboxylic acids during growth. Consequently, most finished cannabis plant material contains only ~1% CBG by dry weight, making it a “minor” cannabinoid.

However, selective breeding has produced CBG-dominant strains and cultivars that produce significantly higher concentrations while remaining low in THC and CBD. CBG-rich plant material is increasingly available as whole-flower products, isolates, and broad-spectrum extracts marketed as dietary supplements.

CBG is a highly lipophilic (fat-soluble) compound with a predicted log P of 7.0–7.5, meaning it accumulates in fatty tissues and requires appropriate solvent-based or lipid-based delivery systems for bioavailability.

How It Works: Receptor Pharmacology and Mechanism of Action

CBG's effects do not primarily derive from cannabinoid receptor activation. Instead, CBG is a weak partial agonist at both CB1 and CB2 receptors (with approximately 5- to 27-fold lower binding affinity than THC). Its pharmacological signature emerges from activity at multiple non-cannabinoid targets:

Primary Mechanisms

α2-Adrenergic Receptor Agonism: CBG is a highly potent agonist of α2-adrenergic receptors (EC50 = 0.2–72.8 nM)—far more potent than its CB1/CB2 activity. Activation of these receptors in the central and peripheral nervous system typically produces sedation, decreased heart rate, lowered blood pressure, and dry mouth. This mechanism, while potentially useful in specific clinical contexts, raises safety concerns for unselected populations.

Serotonin 5-HT1A Antagonism: CBG moderately antagonizes the 5-HT1A receptor (KB = 51.9 nM), which modulates mood, anxiety, and stress responses. The functional significance of this antagonism in humans remains unclear.

TRPM8 Antagonism: CBG potently blocks the TRPM8 ion channel (IC50 = 160 nM), which is involved in cold sensation and may have analgesic or anti-inflammatory roles.

Secondary Mechanisms

CBG also exhibits weak agonist activity at TRPA1, TRPV1, TRPV2, TRPV3, and TRPV4 channels—transient receptor potential (TRP) channels implicated in pain, temperature, and inflammatory signaling. Additionally, CBG blocks voltage-gated sodium channels (Nav1.1, Nav1.2, Nav1.5, Nav1.7) and voltage-dependent calcium channels, mechanisms that may underlie analgesic effects. The evidence for endocannabinoid enzyme inhibition (FAAH, DGL, MAGL) is mixed and contradictory across studies.

Bottom line: CBG is a multi-target ligand whose effects are dominated by α2-adrenergic and serotonin pathways, not cannabinoid receptor signaling—a critical distinction from CBD or THC.

What the Research Shows: Current Evidence and Evidence Grades

CBG research remains predominantly in vitro and preclinical. Human clinical trials are extremely limited. Below is an honest summary by purported benefit:

Anti-inflammatory and Pain Relief

Evidence Grade: Preliminary (in vitro)
In vitro studies suggest CBG may reduce inflammatory markers and modulate pain signaling via TRPM8 antagonism and ion channel blockade. However, no robust human trials exist. One small animal study (2021) suggested CBG reduced inflammatory bowel disease markers in mice, but mouse models do not reliably predict human efficacy.

Mood and Anxiety

Evidence Grade: Speculative
CBG's 5-HT1A antagonism is theoretically relevant to mood regulation, but direct evidence of anxiolytic or antidepressant effects in humans is absent. The α2-adrenergic-mediated sedation might superficially resemble anxiolysis but reflects a different mechanism.

Neuroprotection

Evidence Grade: Speculative (in vitro only)
Early cell-based studies hint that CBG may protect neurons, but these findings have not translated to human or animal models with sufficient rigor to warrant clinical recommendation.

Appetite Stimulation

Evidence Grade: Anecdotal
Unlike THC, CBG has no established appetite-stimulating mechanism. Seller claims lack scientific support.

Summary: Most CBG research is in vitro, dose-response studies in humans are absent, and long-term safety data do not exist. Claims of therapeutic benefit remain speculative.

Delivery Methods and Bioavailability

CBG's high lipophilicity (log P ~7) presents bioavailability challenges similar to other cannabinoids:

Oral (Edibles, Capsules, Tinctures)

Onset: 1–3 hours | Duration: 4–8 hours | Bioavailability: 6–20% (highly variable; enhanced by fat-containing meals)

Sublingual (Tincture, Spray)

Onset: 15–30 minutes | Duration: 4–6 hours | Bioavailability: 10–30% (bypasses first-pass hepatic metabolism partially)

Inhalation (Vaporized, Smoked)

Onset: 5–15 minutes | Duration: 2–4 hours | Bioavailability: 30–50%+ (highest absorption)

Topical (Creams, Salves)

Onset: 30 minutes–2 hours | Duration: Localized | Bioavailability: Minimal systemic absorption; primarily local effect (if any)

CBG is metabolized hepatically via CYP2J2 enzyme. Significant drug interactions are possible with other CYP2J2 substrates, though this pathway is less studied than CYP3A4 or CYP2C19 (which metabolize CBD and THC).

Legal and Regulatory Status

Federal (United States)

CBG derived from hemp (cannabis with ≤0.3% THC by dry weight) is legal under the 2018 Farm Bill and subsequent Interim Final Rules. CBG derived from marijuana (Schedule I controlled substance) remains federally illegal. The DEA has not explicitly scheduled CBG as an individual compound, but the source plant determines legality.

State Level

Hemp-derived CBG products are sold in all 50 states, though some states (e.g., Vermont, Oregon) have implemented additional cannabinoid regulations. CBG from marijuana sources is prohibited in non-legalized states and restricted in legalized states to licensed dispensaries.

Quality and Testing

Unlike FDA-approved medications, CBG dietary supplements are not pre-approved for safety or efficacy. Testing for potency, contaminants (pesticides, heavy metals, microbial), and residual solvents is recommended but not federally mandated. Third-party testing from ISO 17025-accredited labs is best practice.

International

CBG is not scheduled under the UN Convention on Psychotropic Substances. Switzerland permits CBG-rich hemp cultivation with ≤1.0% THC as a tobacco substitute. EU regulations vary by member state.

Safety and Side Effects

Known Adverse Effects (from in vitro and limited human anecdote)

• Sedation and fatigue: α2-adrenergic-mediated; most common reported effect
• Dry mouth
• Decreased blood pressure and heart rate (concerning in vulnerable populations)
• Potential mood changes: Speculative; 5-HT1A antagonism is theoretically relevant but unproven in humans

Impairment and Driving

CBG is non-intoxicating and does not impair cognition like THC. However, sedation from α2-adrenergic activation could impair alertness. Test personal response before driving or using machinery.

Tolerance and Dependence

Unknown in humans; no evidence of abuse potential.